About the Authors
- Paul Kotwinski
-
* E-mail: p.kotwinski@nhs.net
Affiliations Department of Cardiology, North and East Hertfordshire NHS Trust, Stevenage, United Kingdom, Institute for Human Health and Performance, University College London, London, United Kingdom, NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and Imperial College, London, United Kingdom
- Gillian Smith
-
Affiliation NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and Imperial College, London, United Kingdom
- Jackie Cooper
-
Affiliation Centre for Cardiovascular Genetics, University College London, London, United Kingdom
- Julie Sanders
-
Affiliations Institute for Human Health and Performance, University College London, London, United Kingdom, Barts Heart Centre, St Bartholemew’s Hospital, Barts Health NHS Trust, London, United Kingdom
- Louise Ma
-
Affiliation Institute for Human Health and Performance, University College London, London, United Kingdom
- Albert Teis
-
Affiliations NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and Imperial College, London, United Kingdom, Cardiovascular Imaging Unit, Cardiology Department, Germans Trias i Pujol University Hospital, Badalona. Barcelona, Spain
- David Kotwinski
-
Affiliations Institute for Human Health and Performance, University College London, London, United Kingdom, The Anaesthetic Department, Derriford Hospital, Plymouth, United Kingdom
- Michael Mythen
-
Affiliations Department of Anaesthesia and Critical Care, University College London Hospital, London, United Kingdom, UCL Institute of Cardiovascular Science and NIHR University College London Hospitals Biomedical Research Centre, London, United Kingdom
- Dudley J. Pennell
-
Affiliation NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and Imperial College, London, United Kingdom
- Alison Jones
-
Affiliation LOC, London, United Kingdom
- Hugh Montgomery
-
Affiliations Institute for Human Health and Performance, University College London, London, United Kingdom, UCL Institute of Cardiovascular Science and NIHR University College London Hospitals Biomedical Research Centre, London, United Kingdom
- on behalf of the Breast cancer Early disease: Toxicity from Therapy with Epirubicin Regimens–Cardiac Assessment and Risk Evaluation (BETTER-CARE) Study Investigators
-
¶The BETTER-CARE Study Investigators are listed in the Acknowledgments
Competing Interests
The authors PK, JS, LM, AT, DK and HM declare they have no not competing interests. DJP receives research funding from Siemens Medical Systems, (Erlangen, Germany), and is a shareholder and director of Cardiovascular Imaging Solutions (London, UK). This does not alter our adherence to PLOS ONE policies on sharing data and materials. AJ is employed by Leaders in Oncology (LOC, London, UK). An affiliation which commenced after this study was complete. This does not alter our adherence to PLOS ONE policies on sharing data and materials. MM declares no completing interests in relation to this study. He declares commercial affiliations which have no relation to this study: paid Consultant Princes Grace Hospital London; Paid Consultant for Deltex; Paid Consultant for Edwards LifeSciences; Consultant Bev MD; University Chair Sponsor at UCL by Smiths Medical; Director Medinspire Ltd; Share holder and Scientific Advisor Medical Defense Technologies LLC (Gastrostim and Entarik); Director QUENCH ltd (Patent holder “QUENCH”). These do not alter our adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: PK GS MM DJP AJ HM. Data curation: PK GS JS AT DK. Formal analysis: PK JC HM. Funding acquisition: PK JC MM DJP AJ HM. Investigation: PK GS JS LM AT AJ. Methodology: PK GS DK DJP AJ HM. Project administration: PK GS JS. Resources: MM DJP HM. Supervision: MM DJP HM. Validation: DJP HM. Writing – original draft: PK JC JS DJP AJ HM. Writing – review & editing: PK GS JC JS LM AT DK MM DJP AJ HM.